<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the ability of <z:chebi fb="0" ids="35664">statins</z:chebi>, the inhibitors of the hydroxymethylglutaryl-<z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase enzyme, to affect endothelial cell activation induced by anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (anti-beta2GPI) antibodies in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Human umbilical vein endothelial cell (HUVEC) activation was evaluated as U937 monocyte <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, E-selectin, and intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule I (ICAM-1) expression by cell enzyme-linked immunosorbent assay and as interleukin-6 (IL-6) <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> (<z:chebi fb="2" ids="33699">mRNA</z:chebi>) expression by <z:chebi fb="40" ids="33697">RNA</z:chebi> protection assay </plain></SENT>
<SENT sid="2" pm="."><plain>E-selectin-specific nuclear factor kappaB (NF-kappaB) DNA-binding activity was evaluated by the gel-shift assay </plain></SENT>
<SENT sid="3" pm="."><plain>HUVECs were activated by polyclonal affinity-purified IgG, human monoclonal IgM anti-beta2GPI antibodies, human recombinant IL-1beta, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha, or <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="38561,38562">Fluvastatin</z:chebi> reduced, in a concentration-dependent manner (1-10 microM), the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> of U937 to HUVECs and the expression of E-selectin and ICAM-1 induced by anti-beta2GPI antibodies as well as by cytokines or LPS </plain></SENT>
<SENT sid="5" pm="."><plain>Another lipophilic <z:chebi fb="0" ids="35664">statin</z:chebi>, <z:chebi fb="0" ids="9150">simvastatin</z:chebi>, displayed similar effects but to a lesser extent than <z:chebi fb="0" ids="38561,38562">fluvastatin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The inhibition of E-selectin expression exerted by <z:chebi fb="0" ids="38561,38562">fluvastatin</z:chebi> was related to the impairment of NF-kappaB binding to DNA </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, the drug attenuated the expression of IL-6 mRNA in HUVEC exposed to anti-beta2GPI antibodies or cytokines </plain></SENT>
<SENT sid="8" pm="."><plain>Incubation of HUVECs with <z:chebi fb="0" ids="25350">mevalonate</z:chebi> (100 microM), concomitantly with <z:chebi fb="0" ids="38561,38562">fluvastatin</z:chebi>, greatly prevented the inhibitory effect of <z:chebi fb="0" ids="35664">statin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Endothelial activation mediated by anti-beta2GPI antibody can be inhibited by <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Because of the suggested role of endothelial cell activation in the pathogenesis of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS), our data provide, for the first time, a rationale for using <z:chebi fb="0" ids="35664">statins</z:chebi> as an additional therapeutic tool in APS </plain></SENT>
</text></document>